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Abstract
Background: Dual antiplatelet therapy (DAPT) is the recommended preventative treatment for secondary ischaemic
events, but increases the risk of bleeding, potentially affecting patients’ health-related quality-of-life (HRQoL). Varied
utility decrements have been used in cost-effectiveness models assessing alternative DAPT regimens, but it is unclear
which of these decrements are most appropriate. Therefore, we reviewed existing sources of utility decrements for
bleeds in patients receiving DAPT and undertook primary research to estimate utility decrements through a patient
elicitation exercise using vignettes and the EuroQol EQ-5D.
Methods: MEDLINE, PubMed and references of included studies were searched. Primary research and decision analytic
modelling studies reporting utility decrements for bleeds related to DAPT were considered. For the primary research
study, 21 participants completed an elicitation exercise involving vignettes describing minor and major bleeds and the
EQ-5D-3 L and EQ-5D-5 L. Utility decrements were derived using linear regression and compared to existing estimates.
Results: Four hundred forty-two citations were screened, of which 12 studies were included for review. Reported utility
decrements ranged from − 0.002 to − 0.03 for minor bleeds and − 0.007 to − 0.05 for major bleeds. Data sources used
to estimate the decrements, however, lacked relevance to our population group and few studies adequately reported
details of their measurement and valuation approaches. No study completely adhered to reimbursement agency
requirements in the UK according to the National Institute for Health and Care Excellence reference case. Our
primary research elicited utility decrements overlapped existing estimates, ranging from − 0.000848 to − 0.00828
for minor bleeds and − 0.0187 to − 0.0621 for major bleeds. However, the magnitude of difference depended on
the instrument, estimation method and valuation approach applied.
Conclusions: Several sources of utility decrements for bleeds are available for use in cost-effectiveness analyses,
but are of limited quality and relevance. Our elicitation exercise has derived utility decrements from a relevant
patient population, based on standardised definitions of minor and major bleeding events, using a validated
HRQoL instrument and have been valued using general population tariffs. We suggest that our utility decrements
be used in future cost-effectiveness analyses of DAPT.
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Background
Dual antiplatelet therapy (DAPT), which is a combination
of aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel
or ticagrelor), with a suggested treatment duration of
6–36 months, [1] is the recommended preventative treat-
ment for secondary ischaemic events after coronary inter-
ventions such as, percutaneous coronary intervention
(PCI), coronary artery bypass grafting (CABG) and med-
ical management of acute coronary syndrome (ACS) [2].
Recently developed P2Y12 inhibitors (prasugrel and tica-
grelor) are associated with more potent antiplatelet effi-
cacy [3, 4] and reduced rates of non-responsiveness [5]
compared to clopidogrel, but come with increased bleed-
ing complications and costs (approximately 25 times the
cost of clopidogrel) [6]. A decision regarding balancing
the risk of bleeds and costs with the expected benefit in is-
chaemic event reduction must, therefore, be made.
Population rates of bleeds when taking DAPT for the
newer P2Y12 inhibitors are relatively unknown, but ini-
tial registry data suggests approximately 14% of patients
on ticagrelor experience a bleed [7]. Population rates are
predicted to be higher than reported in clinical trials due
to the exclusion of high-risk patients and because only
events requiring hospitalisation are generally reported in
trials. The incidence of minor bleeds, which might not
result in patients seeking medical care, has therefore not
been well quantified with estimates ranging from 9 to
38% of patients on DAPT being affected [8–12]. Despite
being considered minor, these events can impact on pa-
tients’ adherence to treatment, [13] thereby increasing
their risk of secondary ischaemic events.
A lack of reliable estimates on the health-related
quality-of-life (HRQoL) impacts of bleeds could lead
to inappropriate decisions about which DAPT regimens
to use in clinical practice. It is not clear to what extent pri-
mary research has determined the impact of bleeding
events on HRQoL or what evidence has been used to
populate existing decision analytic models assessing
DAPT. Furthermore, the National Institute for Health
and Care Excellence (NICE) in the United Kingdom
(UK) requires the use of the EQ-5D-3 L, a generic health
status questionnaire, [14] when assessing the HRQoL im-
pacts of interventions [15]. It is, therefore, important to
identify whether or not health-state utility decrements for
bleeding events (hereafter referred to as ‘utility decre-
ments’) derived from the EQ-5D-3 L are available for use
in cost-effectiveness analyses. The EQ-5D-3 L has been
shown to be a valid, reliable and responsive instrument to
measure HRQoL in patients with ACS, [16, 17] and is a
suitable questionnaire to use to derive such utility decre-
ments. However, it is unclear if the recently developed
EQ-5D-5 L, with improved sensitivity and reduced ceiling
effects, [18] would also be a suitable instrument to esti-
mate the impact of bleeding on HRQoL.
Therefore, our study first aimed to review the evidence
regarding utility decrements of bleeding events in patients
receiving DAPT after coronary interventions. Second, we
sought to derive robust UK utility decrements for use in
future cost-effectiveness analyses of DAPT, through a pa-
tient elicitation exercise using vignettes and both the 3
and 5 level versions of the EQ-5D.
Methods
Literature review and quality assessment
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRSIMA) statement [19] was used as
a guideline for the design of the review, with adaptations
made due to the focus of utility decrements.
Eligibility criteria
Studies published in English, which reported utility dec-
rements associated with bleeds in adults taking DAPT
were considered. Included studies could be primary re-
search that prospectively collected HRQoL information
from which utility decrements could be estimated or de-
cision analytic models of DAPT that incorporated utility
decrements (derived directly from time trade-off/standard
gamble/expert elicitation methods or indirectly using a
health-related quality of life questionnaire like the EQ-5D).
Specific populations considered included patients receiving
DAPT who had previously had a PCI, CABG or ACS
patients receiving medication only. Studies assessing
antiplatelet monotherapy in these populations were
excluded. Studies reporting HRQoL information from
which utility decrements could not be derived (e.g.,
condition-specific, non-preference based HRQoL ques-
tionnaires) were excluded.
Information sources, search and data collection
Two databases (Ovid MEDLINE and PubMed) were
searched from inception to July 23, 2018 (Additional
file 1: Appendix A). Search terms were developed for
three categories: coronary interventions, DAPT nomencla-
ture and HRQoL terminology. In addition, a hand search of
references from included articles was conducted. One
author (B.D.) screened the titles and abstracts of all the cita-
tions identified from the search strategies, reviewed the
full-text articles identified after screening and extracted the
data from the included studies.
Data items and synthesis of results
The synthesis of the literature search results was strati-
fied by study type (primary research or decision analytic
model). Study design, patient population, DAPT regime,
categorisation of bleeding, HRQoL instrument and valu-
ation approach used to estimate health state utility values
and utility decrements for minor, major and other bleeds
reported were extracted. It is quite common for utility
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decrements to be reported in decision analytic modelling
studies with no more than a citation provided and no add-
itional details as to how the decrements were derived. In
such cases, the cited references were also reviewed to ex-
tract information on the derivation methods. The quality
and relevance of the utility decrements identified in each
included study was assessed using the checklist outlined
by Ara, et al. [20]. Note that as part of the checklist the
utility decrements were assess for their adherence to reim-
bursement agency requirements specifically using the
NICE reference case [15].
Patient elicitation exercise using vignettes and EQ-5D
Study design, recruitment and participants
The elicitation exercise was a standalone study con-
ducted alongside a qualitative study involving focus
groups that explored the behaviour of patients who had
received DAPT after a coronary intervention or an acute
coronary event. The focus groups discussed information
seeking, medication changes and adherence to medica-
tions. The elicitation exercise and qualitative study were
run on the same days by different researchers, using the
same participant sample. The qualitative study did not
include any discussion of the elicitation exercise and
therefore its findings are not discussed here.
The participant sample was composed of four separate
groups (two groups each with patients exposed to DAPT
for either ≤6 or > 6 months), ranging from three to seven
participants. The target sample size was ten participants
per group (total 40 participants). This was a pragmatic
decision aimed to maximise the number of respondents
for the elicitation exercise, but given the participant sample
was shared the number of participants and required num-
ber of groups had to also be manageable for the qualitative
study. Potential participants were identified from hospital
wards pre-discharge and hospital theatre/catheter labora-
tory lists. Of the 150 individuals eligible for inclusion and
approached by telephone, 68 were invited to participate in
the study, of which 37 agreed to participate and received a
participant information leaflet, however, 16 did not attend
their assigned group session resulting in a sample size of
21 participants (Additional file 1: Appendix B). The 21 par-
ticipants who attended the group sessions were, however,
representative of the eligible pool of patients from which
they were drawn (Additional file 1: Appendix C). That is,
demographics and treatment characteristics were broadly
similar between those who were invited to participate in
the study, but did not attend (n = 47) and those who did
attend a group session (n = 21).
Data collection
Participants were randomly allocated a colour-coded study
booklet (Additional file 1: Appendix D), containing a
patient-demographics questionnaire and one of four
sequences of six EQ-5D questionnaires and associated
vignettes (Table 1). The sequence of the EQ-5D ques-
tionnaires and vignettes were varied to avoid ordering
effects in participants’ responses. Study booklet alloca-
tion used a randomisation scheme with block sizes of
two, four and six, stratified by duration of DAPT expos-
ure (≤6 or > 6 months).
Participants first completed the demographics and base-
line EQ-5D-3 L and EQ-5D-5 L questionnaires as they
pertained to their health on that day. As the EQ-5D-3 L is
the NICE recommended instrument for assessing the
HRQoL impacts of interventions its inclusion allowed our
derived decrements to constitute potential evidence for
future cost-effectiveness analyses conducted in the UK. In-
clusion of the EQ-5D-5 L allowed us to compare the mag-
nitude of utility decrements derived from different EQ-5D
questionnaires. Participants then completed EQ-5D-3 L
and EQ-5D-5 L modified questionnaires in relation to
two vignettes describing minor (Vignette A) and major
(Vignette B) bleeds (Additional file 1: Appendix D).
Modified versions of the EQ-5D questionnaires were
approved by the EuroQoL Research Foundation on
June 21, 2017 and used to improve the clarity of the
elicitation exercise (e.g., questionnaires completed in
relation to vignettes rather than the respondent’s “own”
health) and to minimise the burden on participants (e.g.,
removal of the Visual Analogue Scale). Vignettes were
used because there are few opportunities to administer
HRQoL questionnaires to patients experiencing bleeds.
Patients may not seek medical care for minor bleeds, pre-
cluding researchers from interacting with patients at the
time of event and major bleeds often represent medical
emergencies incapacitating patients.
The vignettes were developed based on the Bleeding
Academic Research Consortium (BARC) definitions,
[21] which provided standardised nomenclature to dif-
ferentiate the descriptions of minor (i.e., a bleed that
doesn’t result in patients seeking medical care) and
major (i.e., a bleed that does result in patients seeking
medical care) bleeds. Both vignettes were also reviewed
for face validity and updated based on feedback re-
ceived from two clinicians (a general practitioner and
cardiologist). For each vignette, participants completed
both the EQ-5D-3 L and EQ-5D-5 L. All participants
completed each of the questionnaires individually and did
not discuss their answers with other participants. At the
bottom of each EQ-5D questionnaire, a supplementary
question asked how long participants expected their
HRQoL to be affected by the bleed described in the vi-
gnette. We expected that this information would be poorly
quantified in the literature, yet this information is essential
to estimate appropriate utility decrements (i.e., it is required
to standardise the loss in HRQoL estimated from the
EQ-5D for a specific time period). Therefore, we sought to
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directly quantify values by asking study participants. It
should also be noted that many of the participants (48%;
10/21) reported previously experiencing a minor bleed
while on DAPT during the focus group interviews and
research has shown that most patients who have or are cur-
rently receiving DAPT are cognisant of the range of bleed-
ing risks associated with DAPT [22]. It is therefore likely
that all participants would have actively considered the risk
of bleeding separately from the elicitation exercise, thus
making them suitable surrogates to comment on the im-
pact of bleeding on HRQoL.
Missing data and extreme values
As the elicitation exercise was conducted in small groups
with oversight from at least one study coordinator, missing
data was anticipated to be minimal. Due to the open-ended
nature of the supplementary questions there was the poten-
tial for participants to report extreme values relative to
other participants (the limit for defining an extreme value
was a difference of greater than six months or one year
from the next closest reported value for minor and major
bleeds respectively) or nonsensical values (e.g., HRQoL
time impact greater for minor bleed than major bleeds). In
such scenarios, we planned to consider reported values as
missing and substitute mean values.
Data analysis
Responses to the EQ-5D questionnaires were used to
estimate mean utility decrements for both minor and
major bleeds. Responses were converted to health state
utility values using the UK EQ-5D-3 L tariff, [23] UK
EQ-5D-5 L tariff, [24] and UK EQ-5D-5 L crosswalk to
UK EQ-5D-3 L value set [25]. The latter uses a mapping
function to convert EQ-5D-5 L responses to health state
utility values from the EQ-5D-3 L tariff. Utility decrements
were then derived using linear regression as the primary
analysis. EQ-5D-3 L or EQ-5D-5 L utility values associated
with either Vignette A or Vignette B were the dependent
variable adjusted for baseline EQ-5D utility value, age, sex,
coronary intervention received (PCI, CABG or ACS with
medical management) and days since commencing DAPT
therapy. Control groups were created by duplicating base-
line utility values and assuming these values represented
hypothetical participants not experiencing a bleed. The
regression coefficient for the variable indicating the pres-
ence/absence of a bleed represented the mean utility decre-
ment if the effects on HRQoL were to persist for one-year.
Using responses from the supplementary questions, the re-
gression coefficients of the bleeding event identifier vari-
ables were multiplied by the mean number of days the
event was predicted to affect HRQoL and the product
divided by 365 days.
An alternative approach to estimating utility decrements
was used in a sensitivity analysis to test the robustness of
the decrements derived from the primary analysis. By sub-
tracting the utility values for Vignette A or B from a value
of one (perfect health), a utility decrement for a bleed if
the effects on HRQoL were to persist for one-year for
each participant was estimated. Adjustments were made
by multiplying these values by the mean number of days
the event was predicted to affect HRQoL (derived from
the supplementary questions) and dividing the product by
365 days. The mean decrements for the two bleed types
were then determined. Note that the calculation approach
used in the sensitivity analysis will exaggerate the utility
decrement for any patient not otherwise describing their
health as perfect and was used to identify maximum
plausible values for the minor and major bleeding utility
decrements.
Utility decrements from the primary analysis for each
EQ-5D questionnaire were compared to each other as
well as to decrements from the sensitivity analysis and
estimates from our literature review. As it is likely that
existing utility decrements identified in our literature review
might have been derived for use in cost-effectiveness ana-
lyses from the US perspective, responses to the EQ-5D-3 L
and EQ-5D-5 L were also converted to health state utility
values using the US EQ-5D-3 L tariff [26] and the US
EQ-5D-5 L crosswalk to US EQ-5D-3 L value set [25]. The
primary and sensitivity analyses were repeated and the re-
sults compared to utility decrements identified in our litera-
ture review.
Results
Literature review
Study selection
We identified a total of 459 citations. After removing
duplicates (n = 86), 373 unique titles and abstracts were
Table 1 Different sequences of the six EQ-5D questionnaires for the patient elicitation exercise
Sequence
Number
Order of the questionnaires
1st questionnaire 2nd questionnaire 3rd questionnaire 4th questionnaire 5th questionnaire 6th questionnaire
1 EQ-5D-3 L Baseline EQ-5D-5 L Baseline EQ-5D-3 L Vignette A EQ-5D-3 L Vignette B EQ-5D-5 L Vignette A EQ-5D-5 L Vignette B
2 EQ-5D-5 L Baseline EQ-5D-3 L Baseline EQ-5D-5 L Vignette A EQ-5D-5 L Vignette B EQ-5D-3 L Vignette A EQ-5D-3 L Vignette B
3 EQ-5D-3 L Baseline EQ-5D-5 L Baseline EQ-5D-3 L Vignette B EQ-5D-3 L Vignette A EQ-5D-5 L Vignette B EQ-5D-5 L Vignette A
4 EQ-5D-5 L Baseline EQ-5D-3 L Baseline EQ-5D-5 L Vignette B EQ-5D-5 L Vignette A EQ-5D-3 L Vignette B EQ-5D-3 L Vignette A
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screened. Of these, 330 were excluded and 43 were
reviewed in full-text. Twelve studies were judged eligible
and included in the review (Fig. 1).
Existing utility decrements
The 12 eligible studies comprised two primary research
studies [10, 11] and ten decision analytic modelling studies
[27–36] (Tables 2 and 3 respectively). Utility decrements
from the primary research studies, derived using differ-
ences in baseline and six-month follow-up responses from
the EQ-5D-3 L, ranged from − 0.0257 (95% CI -0.0365
to − 0.0148) for minor bleeds to − 0.0445 (95% CI -0.073
to − 0.016) for major bleeds (Table 2). Utility decrements
from decision analytic models ranged from − 0.002 to −
0.02 for minor bleeds and − 0.007 to − 0.05 for major
bleeds. Utility decrements were also reported for general
bleeding terms such as ‘gastrointestinal bleeds’ ranging
from − 0.005 to − 0.016 and decrements of − 0.01, − 0.02,
− 0.03, − 0.13 and − 0.25 were reported for ‘CABG-related’,
‘bleeding in general’, ‘extra-cranial’, ‘serious’ and ‘non-fatal
bleeds’ respectively (Table 3). A summary of the sources
of utility decrements reported in decision analytic models
is provided in Additional file 1: Appendix E.
Quality and relevance assessment
Based on the information provided in the text of the
included studies as well as in associated references, the
results of our quality and relevance assessment is pro-
vided in Additional file 1: Appendix F. Overall, the
utility decrements for bleeding events from the in-
cluded studies were derived mainly from studies with
limited relevance to the population of interest and
lacked comprehensive reporting to accurately assess
their risk of bias. Only half the studies provided ad-
equate details concerning the measurement and valu-
ation of the reported utility decrements and all the
included studies were not completely aligned with re-
imbursement agency requirements in the UK.
Fig. 1 Flow diagram for selection of studies
Doble et al. Health and Quality of Life Outcomes  (2018) 16:191 Page 5 of 15
Ta
b
le
2
U
til
ity
de
cr
em
en
ts
fo
r
bl
ee
di
ng
ev
en
ts
du
rin
g
du
al
an
tip
la
te
le
t
th
er
ap
y
fro
m
pr
im
ar
y
re
se
ar
ch
st
ud
ie
s
A
ut
ho
r
C
ou
nt
ry
[re
f]
St
ud
y
de
si
gn
Pa
tie
nt
po
pu
la
tio
n
A
nt
ip
la
te
le
t
re
gi
m
e
D
ef
in
iti
on
an
d
ca
te
go
ris
at
io
n
of
bl
ee
di
ng
In
st
ru
m
en
t
us
ed
to
m
ea
su
re
Q
oL
Va
lu
at
io
n
m
et
ho
d
U
til
ity
de
cr
em
en
ts
fo
r
an
y
bl
ee
d
U
til
ity
de
cr
em
en
ts
fo
r
m
in
or
bl
ee
ds
U
til
ity
de
cr
em
en
ts
fo
r
m
aj
or
bl
ee
ds
A
m
in
U
S
[1
0]
Pr
os
pe
ct
iv
e,
m
ul
tic
en
tr
e
co
ho
rt
st
ud
y
(T
RI
U
M
P)
35
60
A
M
I
pa
tie
nt
s
w
ho
ha
d
be
en
ho
sp
ita
lis
ed
D
A
PT
po
st
A
M
I(
84
.9
%
an
d
13
%
of
pa
tie
nt
s
th
at
ha
d
a
nu
is
an
ce
bl
ee
d
at
an
y
tim
e
po
in
t
re
ce
iv
ed
th
ie
no
py
rid
in
e
an
d
w
ar
fa
rin
re
sp
ec
tiv
el
y
at
di
sc
ha
rg
e)
N
ui
sa
nc
e
bl
ee
di
ng
(B
A
RC
ty
pe
1b
),
as
th
e
oc
cu
rr
en
ce
of
an
y
of
th
e
fo
ur
br
ui
si
ng
/
bl
ee
di
ng
ev
en
ts
c
th
at
di
d
no
t
le
ad
to
:h
os
pi
ta
lis
at
io
n,
bl
oo
d
tr
an
sf
us
io
n
or
ch
an
ge
of
m
ed
ic
at
io
ns
by
a
ph
ys
ic
ia
n
EQ
-5
D
VA
S
at
ba
se
lin
e,
1,
6
an
d
12
m
on
th
s
VA
S
N
R
BA
RC
ty
pe
1:
−
2.
81
(9
5%
C
I
1.
09
to
5.
64
)
fo
r
VA
S
at
1
m
on
th
N
R
A
m
in
U
S
[1
1]
Pr
os
pe
ct
iv
e,
ob
se
rv
at
io
na
l,
lo
ng
itu
di
na
l,
m
ul
tic
en
tr
e
re
gi
st
ry
(T
RA
N
SL
A
TE
-A
C
S)
9,
29
0a
A
M
I
pa
tie
nt
s
tr
ea
te
d
w
ith
PC
I
D
A
PT
po
st
PC
I
(c
lo
pi
do
gr
el
in
68
%
,
pr
as
ug
re
li
n
29
%
an
d
tic
ag
re
lo
r
in
2%
)
A
ny
bl
ee
di
ng
or
se
ve
re
br
ui
si
ng
ev
en
t
th
at
w
as
pa
tie
nt
-r
ep
or
te
d,
as
so
ci
at
ed
w
ith
an
an
tip
la
te
le
t
m
ed
ic
at
io
n
ch
an
ge
,o
r
in
de
pe
nd
en
tly
ad
ju
di
ca
te
d
bl
ee
di
ng
re
ho
sp
ita
lis
at
io
n
ba
se
d
on
m
ed
ic
al
re
co
rd
re
vi
ew
;B
A
RC
b
EQ
-5
D
-3
L
qu
es
tio
nn
ai
re
to
ca
lc
ul
at
e
in
de
x
sc
or
e
an
d
VA
S
at
ba
se
lin
e
an
d
6
m
on
th
s
D
1
va
lu
at
io
n
m
od
el
[2
6]
fo
r
in
de
x
sc
or
e
an
d
di
re
ct
va
lu
at
io
n
us
in
g
VA
S
Bl
ee
di
ng
as
so
ci
at
ed
w
ith
a
ch
an
ge
of
−
0.
03
3
(9
5%
C
I
-0
.0
41
to
−
0.
02
6)
in
in
de
x
sc
or
e
an
d
−
2.
5
(9
5%
C
I
-3
.3
to
−
1.
8)
in
VA
S
BA
RC
ty
pe
1
vs
no
ne
:
−
0.
02
57
(9
5%
C
I
-0
.0
36
5
to
−
0.
01
48
)
fo
r
in
de
x
sc
or
e;
−
2.
04
(9
5%
C
I
-3
.1
5
to
−
0.
09
3)
fo
r
VA
S
BA
RC
ty
pe
2–
4
vs
no
ne
:
−
0.
03
81
(9
5%
C
I
-0
.0
47
to
−
0.
02
93
)
fo
r
in
de
x
sc
or
e;
−
2.
79
(9
5%
C
I-
3.
70
to
−
1.
88
)
fo
r
VA
S
BA
RC
ty
pe
3–
4
vs
no
ne
:
−
0.
04
45
(9
5%
C
I-
0.
07
3
to
−
0.
01
6)
fo
r
in
de
x
sc
or
e;
−
7.
10
(9
5%
C
I-
10
.0
4
to
−
4.
16
)
fo
r
VA
S
A
M
Ia
cu
te
m
yo
ca
rd
ia
li
nf
ar
ct
io
n,
BA
RC
Bl
ee
di
ng
A
ca
de
m
ic
Re
se
ar
ch
C
on
so
rt
iu
m
,C
Ic
on
fid
en
ce
in
te
rv
al
,D
A
PT
du
al
an
tip
la
te
le
t
th
er
ap
y,
N
R
no
t
re
po
rt
ed
,P
CI
pe
rc
ut
an
eo
us
co
ro
na
ry
in
te
rv
en
tio
n,
Q
oL
qu
al
ity
of
lif
e,
TR
A
N
SL
A
TE
-A
CS
Tr
ea
tm
en
t
W
ith
A
de
no
si
ne
D
ip
ho
sp
ha
te
Re
ce
pt
or
In
hi
bi
to
rs
:L
on
gi
tu
di
na
lA
ss
es
sm
en
t
of
Tr
ea
tm
en
t
Pa
tt
er
ns
an
d
Ev
en
ts
A
ft
er
A
cu
te
C
or
on
ar
y
Sy
nd
ro
m
e,
TR
IU
M
P
Tr
an
sl
at
io
na
lR
es
ea
rc
h
In
ve
st
ig
at
in
g
U
nd
er
ly
in
g
D
is
pa
rit
ie
s
in
A
cu
te
M
yo
ca
rd
ia
lI
nf
ar
ct
io
n
Pa
tie
nt
s’
H
ea
lth
St
at
us
,V
A
S
vi
su
al
an
al
og
sc
al
e
a S
ta
rt
ed
w
ith
11
,6
49
pa
tie
nt
s
an
d
ex
cl
ud
ed
th
os
e
w
ho
di
ed
in
ho
sp
ita
l(
n
=
13
)
or
by
6
m
on
th
s
(n
=
10
6)
,t
ho
se
w
ith
m
is
si
ng
ba
se
lin
e
(n
=
76
)
or
6-
m
on
th
EQ
-5
D
da
ta
(n
=
19
28
)
an
d
th
os
e
w
ith
in
co
m
pl
et
e
m
ed
ic
al
re
co
rd
s
or
w
ho
se
ho
sp
ita
lis
at
io
n
ev
en
ts
co
ul
d
no
t
be
va
lid
at
ed
(n
=
23
6)
b
Se
e
M
eh
ra
n
et
al
.[
21
]
fo
r
th
e
de
fin
iti
on
s
of
th
e
ni
ne
BA
RC
bl
ee
di
ng
ty
pe
s
(t
yp
e
0,
ty
pe
1,
ty
pe
2,
ty
pe
3a
,t
yp
e
3b
,t
yp
e
3c
,t
yp
e
4,
ty
pe
5a
an
d
ty
pe
5b
)
c N
ui
sa
nc
e
bl
ee
di
ng
w
as
as
se
ss
ed
vi
s
th
e
fo
llo
w
in
g
fo
ur
qu
es
tio
ns
:“
Si
nc
e
le
av
in
g
th
e
ho
sp
ita
la
ft
er
yo
ur
he
ar
t
at
ta
ch
,h
av
e
yo
u
ha
d:
1)
ea
sy
or
si
gn
ifi
ca
nt
bl
ee
di
ng
?;
2)
si
gn
ifi
ca
nt
br
ui
si
ng
?;
3)
gu
m
bl
ee
ds
or
no
se
bl
ee
d?
;o
r
4)
se
rio
us
bl
ee
di
ng
?”
Doble et al. Health and Quality of Life Outcomes  (2018) 16:191 Page 6 of 15
Ta
b
le
3
U
til
ity
de
cr
em
en
ts
fo
r
bl
ee
di
ng
ev
en
ts
du
rin
g
du
al
an
tip
la
te
le
t
th
er
ap
y
fro
m
de
ci
si
on
an
al
yt
ic
m
od
el
s
A
ut
ho
r
[re
f]
H
yp
ot
he
tic
al
pa
tie
nt
po
pu
la
tio
n
m
od
el
le
d
A
nt
ip
la
te
le
t
re
gi
m
e
D
ef
in
iti
on
an
d
ca
te
go
ris
at
io
n
of
bl
ee
di
ng
In
st
ru
m
en
t
an
d
po
pu
la
tio
n
us
ed
to
m
ea
su
re
Q
oL
Va
lu
at
io
n
m
et
ho
d
U
til
ity
de
cr
em
en
ts
fo
r
m
in
or
bl
ee
ds
U
til
ity
de
cr
em
en
ts
fo
r
m
aj
or
bl
ee
ds
U
til
ity
de
cr
em
en
ts
fo
r
ot
he
r
bl
ee
ds
G
re
en
ha
lg
h
[2
7]
Fo
ur
su
bg
ro
up
s:
A
C
S
w
ith
PC
If
or
ST
EM
Iw
ith
an
d
w
ith
ou
t
T2
D
M
;a
nd
A
C
S
w
ith
PC
If
or
U
A
or
N
ST
EM
Iw
ith
an
d
w
ith
ou
t
T2
D
M
D
A
PT
–
pr
as
ug
re
l
pl
us
lo
w
-d
os
e
as
pi
rin
co
m
pa
re
d
to
cl
op
id
og
re
lp
lu
s
lo
w
-d
os
e
as
pi
rin
M
S
m
od
el
de
fin
iti
on
fo
r
bl
ee
d
do
es
no
t
ex
cl
ud
e
C
A
BG
-r
el
at
ed
bl
ee
ds
;n
on
-fa
ta
l
bl
ee
ds
no
t
tr
ea
te
d
as
on
-g
oi
ng
he
al
th
st
at
es
w
ith
in
m
od
el
[s
uc
h
ev
en
ts
in
cu
r
on
ly
te
m
po
ra
ry
re
du
ct
io
n
(1
4
da
ys
)
in
H
RQ
oL
]
M
S:
EQ
-5
D
-3
L;
U
K
po
pu
la
tio
n
no
rm
s
M
S:
Ti
m
e
tr
ad
e-
of
f
te
ch
ni
qu
es
N
R
M
S:
25
%
de
cr
em
en
t
to
U
K
po
pu
la
tio
n
no
rm
s
(fr
ee
of
di
se
as
e)
fo
r1
4
da
ys
;e
qu
al
to
a
di
su
til
ity
of
−
0.
00
7
N
R
G
ar
g
[2
8]
A
C
S
w
ith
PC
I(
i.e
.,
D
ES
)
D
A
PT
-
cl
op
id
og
re
l
pl
us
lo
w
-d
os
e
as
pi
rin
;
du
ra
tio
ns
of
12
an
d
30
m
on
th
s
M
aj
or
an
d
m
in
or
bl
ee
ds
ba
se
d
on
TI
M
I
bl
ee
di
ng
ris
k
sc
or
e
[d
is
ut
ili
ty
ap
pl
ie
d
du
rin
g
th
e
ye
ar
in
w
hi
ch
ev
en
t
oc
cu
rr
ed
]
N
R
–
se
e
A
dd
iti
on
al
fil
e
1:
A
pp
en
di
x
E
fo
r
m
or
e
de
ta
ils
N
R
–
se
e
A
dd
iti
on
al
fil
e
1:
A
pp
en
di
x
E
fo
r
m
or
e
de
ta
ils
−
0.
00
2
−
0.
02
5
N
R
Ka
zi
[2
9]
A
C
S
w
ith
PC
I
Fi
ve
st
ra
te
gi
es
:
1)
ge
ne
ric
cl
op
id
og
re
l;
2)
pr
as
ug
re
l;
3)
tic
ag
re
lo
r;
4)
C
YP
2C
19
ca
rr
ie
rs
tic
ag
re
lo
r
an
d
no
nc
ar
rie
rs
cl
op
id
og
re
l;
5)
C
YP
2C
19
ca
rr
ie
rs
pr
as
ug
re
la
nd
no
nc
ar
rie
rs
cl
op
id
og
re
l
M
in
or
ha
em
or
rh
ag
e
an
d
C
A
BG
-r
el
at
ed
bl
ee
di
ng
ba
se
d
on
TI
M
Ib
le
ed
in
g
ris
k
sc
or
e
an
d
ex
tr
ac
ra
ni
al
ha
em
or
rh
ag
e
ba
se
d
on
TI
M
Is
co
re
N
R
–
se
e
A
dd
iti
on
al
fil
e
1:
A
pp
en
di
x
E
fo
r
m
or
e
de
ta
ils
N
R
–
se
e
A
dd
iti
on
al
fil
e
1:
A
pp
en
di
x
E
fo
r
m
or
e
de
ta
ils
0.
2
fo
r
2
da
ys
(−
0.
00
4)
N
R
Ex
tr
a-
cr
an
ia
l:
0.
2
fo
r
14
da
ys
(−
0.
03
08
)
C
A
BG
-r
el
at
ed
bl
ee
d:
0.
5
fo
r
7
da
ys
(−
0.
01
)
Li
ew
[3
0]
A
C
S
(t
ria
ld
at
a
us
ed
in
cl
ud
ed
pa
tie
nt
s
sc
he
du
le
d
to
un
de
rg
o
m
ed
ic
al
or
in
va
siv
e
m
an
ag
em
en
t
(e
.g
.,
PC
Io
rC
A
BG
)
D
A
PT
–
tic
ag
re
lo
r
pl
us
as
pi
rin
co
m
pa
re
d
to
cl
op
id
og
re
lp
lu
s
as
pi
rin
N
o
cl
in
ic
al
de
fin
iti
on
s
re
po
rt
ed
[d
is
ut
ili
tie
s
ap
pl
ie
d
du
rin
g
th
e
cy
cl
e
(1
-y
ea
r
cy
cl
e
le
ng
th
)
in
w
hi
ch
th
e
ev
en
t
oc
cu
rr
ed
]
EQ
-5
D
-3
L
N
R
−
0.
02
−
0.
05
N
R
G
up
ta
[3
1]
C
A
S
w
ith
PC
I
re
ce
iv
in
g
ei
th
er
D
ES
or
BM
S
D
A
PT
-
cl
op
id
og
re
l
pl
us
as
pi
rin
G
Ib
le
ed
in
g
Ba
se
d
on
th
e
av
er
ag
e
du
ra
tio
n
of
ho
sp
ita
lis
at
io
n
N
A
N
R
N
R
G
Ih
ae
m
or
rh
ag
e:
to
ll
of
6
da
ys
(−
0.
01
6)
Doble et al. Health and Quality of Life Outcomes  (2018) 16:191 Page 7 of 15
Ta
b
le
3
U
til
ity
de
cr
em
en
ts
fo
r
bl
ee
di
ng
ev
en
ts
du
rin
g
du
al
an
tip
la
te
le
t
th
er
ap
y
fro
m
de
ci
si
on
an
al
yt
ic
m
od
el
s
(C
on
tin
ue
d)
A
ut
ho
r
[re
f]
H
yp
ot
he
tic
al
pa
tie
nt
po
pu
la
tio
n
m
od
el
le
d
A
nt
ip
la
te
le
t
re
gi
m
e
D
ef
in
iti
on
an
d
ca
te
go
ris
at
io
n
of
bl
ee
di
ng
In
st
ru
m
en
t
an
d
po
pu
la
tio
n
us
ed
to
m
ea
su
re
Q
oL
Va
lu
at
io
n
m
et
ho
d
U
til
ity
de
cr
em
en
ts
fo
r
m
in
or
bl
ee
ds
U
til
ity
de
cr
em
en
ts
fo
r
m
aj
or
bl
ee
ds
U
til
ity
de
cr
em
en
ts
fo
r
ot
he
r
bl
ee
ds
Sc
hl
ei
ni
tz
[3
2]
H
ig
h-
ris
k
A
C
S:
un
st
ab
le
an
gi
na
an
d
el
ec
tr
oc
ar
di
og
ra
ph
ic
ch
an
ge
s
or
no
n-
Q
-
w
av
e
M
I
D
A
PT
–
cl
op
id
og
re
l
pl
us
as
pi
rin
co
m
pa
re
d
to
as
pi
rin
al
on
e
G
Ib
le
ed
in
g
A
ss
um
pt
io
n
N
A
N
R
N
R
G
Ib
le
ed
in
g:
−
0.
00
5
La
to
ur
-P
er
ez
[3
3]
N
ST
EM
IA
C
S
w
ith
ho
sp
ita
la
dm
is
si
on
D
A
PT
-
cl
op
id
og
re
l
pl
us
as
pi
rin
co
m
pa
re
d
to
as
pi
rin
al
on
e
G
Ib
le
ed
in
g
[d
is
ut
ili
ty
on
ly
co
un
te
d
in
th
e
cy
cl
e
(1
-m
on
th
cy
cl
e
le
ng
th
)
in
w
hi
ch
it
oc
cu
rr
ed
]
N
R
–
se
e
A
dd
iti
on
al
fil
e
1:
A
pp
en
di
x
E
fo
r
m
or
e
de
ta
ils
N
R
–
se
e
A
dd
iti
on
al
fil
e
1:
A
pp
en
di
x
E
fo
r
m
or
e
de
ta
ils
N
R
N
R
Se
rio
us
ha
em
or
rh
ag
e
di
su
til
ity
−
0.
13
;G
I
bl
ee
di
ng
re
fe
rr
ed
to
in
m
et
ho
ds
se
ct
io
n,
bu
t
no
as
so
ci
at
ed
di
su
til
ity
va
lu
e
re
po
rt
ed
Jia
ng
[3
4]
A
C
S
w
ith
PC
I
D
A
PT
–
Th
re
e
st
ra
te
gi
es
:
1)
cl
op
id
og
re
lp
lu
s
as
pi
rin
;2
)
pr
as
ug
re
l
or
tic
ag
re
lo
r
pl
us
as
pi
rin
;a
nd
3)
C
YP
2C
19
LO
F/
G
O
F
al
le
le
pr
as
ug
re
lo
r
tic
ag
re
lo
r
pl
us
as
pi
rin
an
d
w
ild
ty
pe
cl
op
id
og
re
lp
lu
s
as
pi
rin
N
on
fa
ta
lb
le
ed
in
g
N
R
–
se
e
A
dd
iti
on
al
fil
e
1:
A
pp
en
di
x
E
fo
r
m
or
e
de
ta
ils
N
R
–
se
e
A
dd
iti
on
al
fil
e
1:
A
pp
en
di
x
E
fo
r
m
or
e
de
ta
ils
N
R
N
R
N
on
fa
ta
lb
le
ed
in
g:
−
0.
25
0
W
an
g
[3
5]
60
-y
ea
r
ol
d
C
hi
ne
se
(N
or
th
A
si
an
)
A
C
S
pa
tie
nt
s
w
ho
un
de
rw
en
t
PC
I
D
A
PT
–
Th
re
e
st
ra
te
gi
es
:
1)
cl
op
id
og
re
lp
lu
s
as
pi
rin
;2
)
tic
ag
re
lo
r
pl
us
as
pi
rin
;a
nd
3)
C
YP
2C
19
*2
al
le
le
ca
rr
ie
rs
re
ce
iv
e
tic
ag
re
lo
r
pl
us
as
pi
rin
an
d
w
ild
ty
pe
cl
op
id
og
re
lp
lu
s
as
pi
rin
Bl
ee
di
ng
N
R
–
se
e
A
dd
iti
on
al
fil
e
1:
A
pp
en
di
x
E
fo
r
m
or
e
de
ta
ils
N
R
–
se
e
A
dd
iti
on
al
fil
e
1:
A
pp
en
di
x
E
fo
r
m
or
e
de
ta
ils
N
R
N
R
Bl
ee
di
ng
:−
0.
02
Jia
ng
[3
6]
60
-y
ea
r
ol
d
A
C
S
pa
tie
nt
s
un
de
rg
oi
ng
PC
I
D
A
PT
–
Fo
ur
st
ra
te
gi
es
:
1)
cl
op
id
og
re
lp
lu
s
as
pi
rin
;2
)
pr
as
ug
re
l
or
tic
ag
re
lo
r
pl
us
as
pi
rin
;3
)
C
YP
2C
19
LO
F/
G
O
F
al
le
le
pr
as
ug
re
lo
rt
ic
ag
re
lo
r
N
on
fa
ta
lb
le
ed
in
g
N
R
–
se
e
A
dd
iti
on
al
fil
e
1:
A
pp
en
di
x
E
fo
r
m
or
e
de
ta
ils
N
R
–
se
e
A
dd
iti
on
al
fil
e
1:
A
pp
en
di
x
E
fo
r
m
or
e
de
ta
ils
N
R
N
R
N
on
fa
ta
lb
le
ed
in
g:
−
0.
25
0
Doble et al. Health and Quality of Life Outcomes  (2018) 16:191 Page 8 of 15
Ta
b
le
3
U
til
ity
de
cr
em
en
ts
fo
r
bl
ee
di
ng
ev
en
ts
du
rin
g
du
al
an
tip
la
te
le
t
th
er
ap
y
fro
m
de
ci
si
on
an
al
yt
ic
m
od
el
s
(C
on
tin
ue
d)
A
ut
ho
r
[re
f]
H
yp
ot
he
tic
al
pa
tie
nt
po
pu
la
tio
n
m
od
el
le
d
A
nt
ip
la
te
le
t
re
gi
m
e
D
ef
in
iti
on
an
d
ca
te
go
ris
at
io
n
of
bl
ee
di
ng
In
st
ru
m
en
t
an
d
po
pu
la
tio
n
us
ed
to
m
ea
su
re
Q
oL
Va
lu
at
io
n
m
et
ho
d
U
til
ity
de
cr
em
en
ts
fo
r
m
in
or
bl
ee
ds
U
til
ity
de
cr
em
en
ts
fo
r
m
aj
or
bl
ee
ds
U
til
ity
de
cr
em
en
ts
fo
r
ot
he
r
bl
ee
ds
pl
us
as
pi
rin
an
d
w
ild
ty
pe
cl
op
id
og
re
lp
lu
s
as
pi
rin
;a
nd
4)
lo
w
re
sp
on
de
rs
(P
RU
>
20
8)
cl
op
id
og
re
l
lo
ad
in
g
do
se
fo
llo
w
ed
by
pr
as
ug
re
lo
r
tic
ag
re
lo
rp
lu
s
as
pi
rin
an
d
no
rm
al
re
sp
on
de
rs
(P
RU
≤
20
8)
cl
op
id
og
re
lp
lu
s
as
pi
rin
.
A
CS
ac
ut
e
co
ro
na
ry
sy
nd
ro
m
e,
A
F
at
ria
lf
ib
ril
la
tio
n,
A
G
as
se
ss
m
en
t
gr
ou
p,
BM
S
ba
re
m
et
al
st
en
t,
CA
BG
co
ro
na
ry
ar
te
ry
by
-p
as
s
gr
af
tin
g,
CA
S
co
ro
na
ry
ar
te
ry
st
en
os
is
,D
A
PT
du
al
an
tip
la
te
le
t
th
er
ap
y,
D
ES
dr
ug
-e
lu
tin
g
st
en
t,
G
Ig
as
tr
oi
nt
es
tin
al
,G
O
F
ga
in
-o
f-
fu
nc
tio
n,
H
RQ
oL
he
al
th
-r
el
at
ed
qu
al
ity
of
lif
e,
IC
D
-9
In
te
rn
at
io
na
lS
ta
tis
tic
al
C
la
ss
ifi
ca
tio
n
of
D
is
ea
se
s
an
d
Re
la
te
d
H
ea
lth
Pr
ob
le
m
s
Ve
rs
io
n
9,
LO
S
lo
ss
-o
f-
fu
nc
tio
n
,M
Im
yo
ca
rd
ia
l
in
fa
rc
tio
n,
M
S
m
an
uf
ac
tu
re
r’s
su
bm
is
si
on
,N
A
no
t
ap
pl
ic
ab
le
,N
R
no
t
re
po
rt
ed
,N
ST
EM
In
on
-S
T
se
gm
en
t
el
ev
at
io
n
m
yo
ca
rd
ia
li
nf
ar
ct
io
n,
PA
D
pe
rip
he
ra
la
rt
er
ia
ld
is
ea
se
,P
CI
pe
rc
ut
an
eo
us
co
ro
na
ry
in
te
rv
en
tio
n,
PR
U
P2
Y 1
2
re
ac
tio
n
un
its
,Q
oL
qu
al
ity
of
lif
e,
SD
st
an
da
rd
de
vi
at
io
n,
SG
st
an
da
rd
ga
m
bl
e,
ST
EM
IS
T
se
gm
en
t
el
ev
at
io
n
m
yo
ca
rd
ia
li
nf
ar
ct
io
n,
T2
D
M
ty
pe
2
di
ab
et
es
m
el
lit
us
,T
IM
I[
28
],
U
A
un
st
ab
le
an
gi
na
Doble et al. Health and Quality of Life Outcomes  (2018) 16:191 Page 9 of 15
Patient elicitation exercise using vignettes and EQ-5D
Baseline patient characteristics
Participants were elderly (mean age 66), most were male
(20/21) and all participants reported their ethnicity as
White British (21/21) (Table 4). The majority had received
PCI (14/21) with others receiving CABG (6/21) or medical
management due to ACS (1/21). DAPT exposure time
was ≤6 and > 6 months for nine and 12 of the participants
respectively. Baseline EQ-5D health state utility values
ranged from 0.760 on the EQ-5D-3 L UK tariff and
EQ-5D-5 L to EQ-5D-3 L crosswalk value set to 0.833 on
the EQ-5D-5 L UK tariff.
Missing data and extreme values
All but one participant (20/21) completed the demograph-
ics questionnaire with no missing data; the remaining
participant did not report the number of months over
which they had taken DAPT. The two baseline EQ-5D
questionnaires were completed with no missing data.
Complete data were obtained for the EQ-5D-3 L for both
Vignettes A and B; one participant did not complete the
EQ-5D-5 L for either Vignette A or B; and one participant
only responded to the pain and anxiety/depression do-
mains for the EQ-5D-5 L for Vignette A. In addition, five
participants did not respond to the supplementary ques-
tion (i.e., duration of decrement in HRQoL) for both
Vignette A and B with the EQ-5D-3 L; missing values
were imputed with mean values of 7.60 and 45.38 days re-
spectively. Five and four participants did not respond to
this question for Vignette A and B respectively with the
EQ-5D-5 L; missing values were imputed with mean
values of 10.93 and 48.75 days respectively.
One participant reported extreme values of ten years for
Vignette A and four years for Vignette B for the EQ-5D-5 L
(next closest values were three and ten months respectively),
which is perhaps counterintuitive given Vignette A repre-
sents a less severe health state (minor bleed) compared to
Vignette B (major bleed). The same participant also reported
an extreme value of one year for Vignette A (next closest
value was three months) and no response for Vignette B for
the EQ-5D-3 L. These three extreme values were set to
missing and imputed with the respective mean value.
Utility decrements for minor and major bleeding events
Utility decrements for both minor and major bleeding
events derived using linear regression (primary analysis)
and the alternative approach (sensitivity analysis) are
presented in Table 5. For the primary analysis, the utility
decrements estimated using the two EQ-5D questionnaires
and different valuation methods are relatively similar
(range − 0.000848 to − 0.00250 for minor bleeds and −
0.0187 to − 0.0297 for major bleeds). The EQ-5D-3 L
UK tariff resulted in the largest utility decrement for
both minor and major bleeds (− 0.00250 and− 0.0297 re-
spectively). Applying the US tariff to the EQ-5D-3 L resulted
in slightly smaller decrements (− 0.00180 and − 0.0203). The
EQ-5D-5 L UK tariff resulted in the smallest utility
decrement for minor bleeds (− 0.000848) and a smaller
utility decrement for major bleeds when compared to
the respective value for the EQ-5D-3 L UK tariff (0.0222
versus 0.0297). Utility decrements derived from crosswalk
values were smaller than the values estimated from the
EQ-5D-3 L using both the UK and US tariffs for both
major and minor bleeds (Table 5). Complete regression re-
sults are provided in Additional file 1: Appendix G.
Sensitivity analysis
Using the alternative estimation approach resulted in utility
decrements that were larger compared to the values esti-
mated in the primary analysis (range 0.00453 to 0.00828 for
Table 4 Baseline participant characteristics from the elicitation
exercise
Characteristic Label Mean (range or %)
Age (n = 21) 66.3 (48 to 88)
Sex (n = 21) Female
Male
1 (5%)
20 (95%)
Ethnicity (n = 21) White British 21 (100%)
Coronary intervention
received (n = 21)
PCI
CABG
Medical Management
14 (67%)
6 (29%)
1 (5%)
DAPT exposure time
(n = 21)
≤6 months 9 (43%)
> 6 months 12 (57%)
Months received
DAPT (n = 20)a
7.5 (0 to 15)
Days since starting
DAPT (n = 21)b
235 (18 to 561)
Reported previously
experiencing a minor
bleed while on DAPTc
10 (48%)
EQ-5D-3 L UK tariff (n = 21) 0.760 (0.159 to 1)
EQ-5D-3 L US tariff (n = 21) 0.816 (0.446 to 1)
EQ-5D-5 L UK tariff (n = 21) 0.824 (0.197 to 1)
EQ-5D-5 L UK crosswalk
(n = 21)
0.760 (0.221 to 1)
EQ-5D-5 L US crosswalk
(n = 21)
0.817 (0.440 to 1)
CABG coronary artery bypass grafting, DAPT dual antiplatelet therapy, PCI
percutaneous coronary intervention
aThis is self-reported from the patient-demographics questionnaire; a value of
zero for this variable indicates that the participant had received DAPT for less
than a month
bDays between the date of the focus group and the date the participant
commenced DAPT therapy. The date the participant commenced DAPT
therapy was derived from the screening questionnaire used
during recruitment
cThis information was not collected in the patient-demographics
questionnaire, but rather ascertained in the discussions that occurred during
the qualitative interviews that were conducted as part of a separate study
using the same participant sample that completed the elicitation exercise
Doble et al. Health and Quality of Life Outcomes  (2018) 16:191 Page 10 of 15
minor bleeds and 0.0405 to 0.0621) (Table 5). The relative
magnitude of the utility decrements followed the same pat-
tern as observed in the primary analysis. For both minor
and major bleeds, the largest difference between the utility
decrements estimated in the primary and sensitivity
analyses was for the EQ-5D-3 L UK tariff (difference of
0.00578 and 0.0324 respectively).
Comparing utility decrements from all sources
An ordering by magnitude of the derived and existing util-
ity decrements for minor and major bleeds is presented in
Table 6. For minor bleeds the utility decrements range
from − 0.000848 to − 0.0257. Whereas, for major bleeds
the utility decrements ranged from − 0.005 to − 0.250.
Discussion
The evidence of utility decrements for bleeds in patients
receiving DAPT after coronary interventions is limited.
Data sources used to estimate utility decrements lack
relevance to the population of interest and have been in-
adequately reported, precluding an accurate assessment
of their susceptibility to bias. Adequate details of meas-
urement and valuation are only provided for half the
studies and no study completely aligned with reimburse-
ment agency requirements in the UK according to the
NICE reference case. The highest quality evidence was
reported by Amin et al., [11] but this study used a US
population, applying the EQ-5D-3 L US tariff (limits
generalisability to other jurisdictions). The decrements
were also based on differences in HRQoL estimated over
six-months, which is an overestimation of the length of
time a bleed would affect HRQoL compared to responses
from the supplementary questions in our study (8–11 days
and 45–49 days for minor and major bleeds respectively).
Our primary research study attempted to elicit the length
of time a bleed would affect HRQoL from patients who
either had experienced a minor bleed or were highly likely
to have actively considered the risk of bleeding outside the
elicitation exercise, whereas existing studies have based
this length of time on clinical assumptions or used the
time difference between study follow-up points.
Utility decrements derived from the patient elicitation
exercise were consistent with some of the existing esti-
mates (Table 6). The utility decrement for minor bleeds
estimated from the EQ-5D-3 L UK tariff in the primary
analysis of our study (− 0.00250) is similar to decrements
reported by Garg et al. [28] and Kazi et al. [29] (− 0.002
and − 0.004 respectively) that were both based on an un-
clear synthesis of values reported from the consensus of
three internists [37] and a direct elicitation using standard
gamble methods [38]. In contrast, there is a large differ-
ence in the decrements estimated from the EQ-5D-3 L US
tariff in the primary and sensitivity analysis for our study
(− 0.00180 and − 0.00584 respectively) and the decrement
reported by Amin et al. [11] who also used the EQ-5D-3 L
US tariff (− 0.0257). In comparison to EQ-5D-3 L US tariff
utility decrements for other conditions [39] the utility dec-
rement for minor bleeding reported by Amin et al. seems
large. Similar decrements are reported for mononeuritis
of the upper limb (− 0.0244), chronic ulcer of the skin
(− 0.0272) and migraine (− 0.0297). These conditions
would seem to be associated with greater HRQoL affects
compared to minor bleeds, that by the BRAC definition
do not cause patients to seek treatment. In contrast,
Table 5 Utility decrements for minor and major bleeding events using regression-based approach (primary analysis) and alternative
approach (sensitivity analysis); mean (standard deviation)
Instrument Primary Analysis Sensitivity Analysis
Minor Bleeda Major Bleedb Minor Bleedc Major Bleedd
EQ-5D-3 L UK tariff (n = 21) − 0.00250 (0.00265) − 0.0297 (0.0478) − 0.00828 (0.0155) − 0.0621
(0.103)
EQ-5D-3 L US tariff (n = 21) − 0.00180 (0.00190) − 0.0203 (0.0328) − 0.00584 (0.0102) − 0.0441 (0.0705)
EQ-5D-5 L to EQ-5D-3 L UK value set (n = 19; n = 20)e − 0.00140 (0.00280) −0.0258 (0.0421) − 0.00661
(0.00911)
−0.0552 (0.0830)
EQ-5D-5 L to EQ-5D-3 L US value set (n = 19; n = 20)e − 0.00137 (0.00275) −0.0187 (0.0305) − 0.00566 (0.00880) − 0.0405 (0.0597)
EQ-5D-5 L UK tariff (n = 19; n = 20)e − 0.000848 (0.00170) − 0.0222 (0.0362) − 0.00453 (0.00614) −0.0465 (0.0700)
aUtility decrements obtained by multiplying the regression coefficient for the bleeding event identifier variable by the mean number of days (7.60 days for EQ-5D-
3 l and 10.93 for EQ-5D-5 L) that a minor bleed is expected to affect health-related quality-of-life and dividing the product by 365 days
bUtility decrements obtained by multiplying the regression coefficient for the bleeding event identifier variable by the mean number of days (45.38 days for EQ-
5D-3 L and 48.75 for EQ-5D-5 L) that a major bleed is expected to affect health-related quality-of-life and dividing the product by 365 days
cUtility decrements obtained by subtracting the health state utility value associated with Vignette A (minor bleed) from one (perfect health) and multiplying by
the mean number of days (7.60 days for EQ-5D-3 l and 10.93 for EQ-5D-5 L) that a minor bleed is expected to affect health-related quality-of-life and dividing the
product by 365 days
dUtility decrements obtained by subtracting the health state utility value associated with Vignette B (major bleed) from one (perfect health) and multiplying by
the mean number of days (45.38 days for EQ-5D-3 L and 48.75 for EQ-5D-5 L) that a major bleed is expected to affect health-related quality-of-life and dividing
the product by 365 days
eOne participant did not complete the EQ-5D-5 L for either Vignette A or B and one participant only responded to the pain and anxiety domains for the EQ-5D-
5 L for Vignette A resulting in two missing values for minor bleeds and one missing value of major bleeds
Doble et al. Health and Quality of Life Outcomes  (2018) 16:191 Page 11 of 15
the utility decrements for minor bleeds derived in our
study are comparable to decrements reported for chronic
sinusitis (− 0.0022) and other dental disorders (− 0.003),
which would likely have a similar effect on HRQoL as
minor bleeds.
The utility decrements for major bleeds estimated from
the EQ-5D-3 L and EQ-5D-5 L using the UK tariffs in the
primary analysis of our study (− 0.0297 and − 0.0222 re-
spectively) are similar to decrements reported by Garg et al.
[28] and Kazi et al. [29] (− 0.025 and − 0.0381 respectively).
Decrements estimated from the EQ-5D-3 L US tariff in the
primary and sensitivity analysis for our study (− 0.0203
and − 0.0441 respectively) are similar to the decrements
reported by Amin et al. [11] for BARC type 2–4 and
type 3–4 bleeds (− 0.0381 and − 0.0445 respectively).
From our elicitation exercise it is apparent that utility
decrements estimated from the EQ-5D-3 L are consistently
larger than decrements estimated from the EQ-5D-5 L. The
differences in decrements were larger when EQ-5D-3 L
values were compared to EQ-5D-5 L values directly
(differences of 0.00165 and 0.0075 for minor and major
bleeds respectively), with small differences observed
when EQ-5D-3 L values were compared to values obtained
using the EQ-5D-5 L to EQ-5D-3 L crosswalk value set
(differences of 0.0011 and 0.0039 respectively). This is
not surprising, as the EQ-5D-5 L has been shown to
shift mean utility values closer to 1 (full health), com-
pressing them into a smaller range compared to the
EQ-5D-3 L [40]. This difference can potentially cause
improvements in HRQoL to be valued less when using
the EQ-5D-5 L compared to the EQ-5D-3 L, however,
the impact of using utility decrements derived from
the different versions of the EQ-5D on the cost-effect-
iveness of DAPT has yet to be elucidated and will be a
valuable line of future research.
Our study has several limitations. Firstly, our derived util-
ity decrements are based on responses to the EQ-5D asso-
ciated with vignettes describing minor and major bleeds
and responses from participants estimating the length of
time a bleed would impact their HRQoL. Participants com-
pleting the elicitation exercise may not have directly experi-
enced a major bleed, but most had previously experienced
a minor bleed while on DAPT. All participants were, how-
ever, recruited for the study due to their current or past ex-
perience taking DAPT and research has shown that most
patients on DAPT are aware of the range of bleeding risks
associated with DAPT [22]. As such, it is likely that all par-
ticipants would have been informed of the risk of bleeds
while on DAPT by their treating physician, thus, making
them suitable surrogates. Furthermore, the are a number
existing studies that have successfully employed the vi-
gnette approach to eliciting utility values/decrements using
participant samples with no first-hand experience or know-
ledge of the health states they were being asked to value
Table 6 Derived and existing utility decrements for minor and
major bleeds ordered by magnitude
Source Utility decrement for minor bleeds
EQ-5D-5 L UK tariff - PA −0.000848
EQ-5D-5 L to EQ-5D-3 L US
value set - PA
−0.00137
EQ-5D-5 L to EQ-5D-3 L UK
value set - PA
−0.00140
EQ-5D-3 L US tariff - PA −0.00180
Garg [28] − 0.002
EQ-5D-3 L UK tariff - PA −0.00250
Kazi [29] −0.004
EQ-5D-5 L UK tariff - SA −0.00453
EQ-5D-5 L to EQ-5D-3 L US
value set - SA
−0.00566
EQ-5D-3 L US tariff - SA −0.00584
EQ-5D-5 L to EQ-5D-3 L UK
value set - SA
−0.00661
EQ-5D-3 L UK tariff - SA −0.00828
Liew [30] − 0.02
Amin [11] −0.0257 (BARC type 1)
Source Utility decrement for major bleeds
Schleinitz [32] −0.005 (GI bleeding)
Greenhalgh [27] − 0.007
Kazi [29] −0.01 (CABG-related)
Gupta [31] −0.016 (GI haemorrhage)
EQ-5D-5 L to EQ-5D-3 L US
value set - PA
−0.0187
Wang [35] − 0.02 (bleeding in general)
EQ-5D-3 L US tariff - PA −0.0203
EQ-5D-5 L UK tariff - PA −0.0222
Garg [28] − 0.025
EQ-5D-5 L to EQ-5D-3 L UK
value set - PA
−0.0258
EQ-5D-3 L UK tariff - PA −0.0297
Kazi [29] − 0.0308 (extra-cranial)
Amin [11] −0.0381 (BARC type 2–4)
EQ-5D-5 L to EQ-5D-3 L US
value set - SA
−0.0405
EQ-5D-3 L US tariff - SA −0.0441
Amin [11] − 0.0445 (BARC type 3–4)
EQ-5D-5 L UK tariff - SA − 0.0465
Liew [30] −0.05
EQ-5D-5 L to EQ-5D-3 L UK
value set - SA
−0.0552
EQ-5D-3 L UK tariff - SA −0.0621
Latour-Perez [33] − 0.13 (serious haemorrhage)
Jiang [34] −0.250 (non-fatal bleeding)
Jiang [36] −0.250 (non-fatal bleeding)
BARC Bleeding Academic Research Consortium, CABG coronary artery
bypass grafting, GI gastrointestinal, PA primary analysis, SA
sensitivity analysis
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[41–43]. These existing studies have justified the vignette
approach as existing evidence was of poor quality and
relevance (which we also showed in our review) and
that direct measurement in affected patients would be
difficult (which is also the case for major and minor
bleeds as patients are incapacitated and don’t interact
with the healthcare system at the time of the event
respectively).
Secondly, our study population was small (n = 21) and
homogeneous, potentially limiting generalisability. Further-
more, 16 of the 37 participants who agreed to participate in
the study did not attend their assigned group session. The
reasons for non-attendance are not clear, but could be due
to reduced HRQoL, employment status or a greater travel
distance to the study location. These potential differences
may bias our results, but the direction of such bias is un-
clear. That being said, our sample is broadly comparable in
demographic and treatment characteristics to those individ-
uals who were invited to participant, but did not attend
(Additional file 1: Appendix C) as well as to a whole of
England PCI registry that reports demographics of 74%
male and 90% Caucasian [44]. In addition, given the
questionable quality and relevance to the UK context of
the existing evidence identified in our review (some
decrements derived from expert elicitation of only three
medical internists or a single clinician), [28, 29, 33, 35]
we believe that our larger sample and applied methods
represent an improvement compared to approaches
used previously.
Thirdly, the elicitation exercise required cognitive
processing that may have been difficult for some partic-
ipants due to advanced age (some participants were >
80 years old and noticeably fatigued/lost concentration
during the 20 min exercise; this was in addition to an
hour long group discussion). A few participants com-
mented that it was difficult to imagine that they were
the individual described in the vignettes. However, as
the groups were small the study coordinators ensured
that all of the participants understood the exercise and
completed all questionnaires to the best of their ability.
Fourthly, some of the participants reported difficulty
in assessing the impact of a major bleed (i.e., a bleed
that results in patients seeking medical care) on
HRQoL given the range of different examples pre-
sented in the vignette (e.g., persistent nose bleed,
blood in your bowel movement, vomiting blood or
bleeding in your eye). As we were interested in esti-
mating an average utility decrement for a major bleed-
ing event, in general, it was not possible to limit the
vignette description to a specific type of bleed. Fur-
thermore, the vignette for major bleeds was developed
using the BARC definitions, which encompass several con-
cepts of seriousness when classifying bleeds considered
‘major’ [21]. For the few participants expressing difficulty,
guidance from the supervising researcher was provided, in-
dicating that the participant should try to account for all
potential impacts of the bleeds described in the vignette in
their responses. It is, however, possible that participants
limited their responses to the impact of only one of the ex-
ample bleeds described, but it is not clear if participants
would have selected the “less” or more “severe” example
bleed in their responses.
Despite the limitations, the patient elicitation exercise
provides a clear approach to estimating utility decrements
for adverse events that may otherwise be difficult to obtain.
For minor bleeds, alternative approaches such as expert
elicitation might be less reliable, since clinicians have lim-
ited ability to observe the HRQoL impacts of such events
as by definition minor bleeds do not cause patients to seek
medical care [21]. The elicitation exercise also has the
added advantage over direct elicitation approaches like time
trade-off [45] or standard gamble, [46] in that it captures
both the patients’ understandings of the HRQoL impacts
and allows for the use of general population preferences in
estimating utility values as recommended by many reim-
bursement agencies like NICE [15].
Our study has also raised the question of whether the
EQ-5D is a suitable instrument to capture HRQoL im-
pacts of adverse events. This was reflected in our study by
the confusion experienced by many participants when try-
ing to understand why certain questions of the EQ-5D
were relevant to the health state described in the vignettes.
For example, one participant stated: “Why would my abil-
ity to walk be affected by a nose bleed?”. It seemed partici-
pants were expecting questions to be directly related to
the event described in the vignettes, such as those likely to
be included in a preference-based condition-specific
measure of HRQoL. It may, therefore, be of interest to ex-
plore such HRQoL questionnaires when using the patient
elicitation vignette approach.
Conclusion
Overall, the choice of utility decrement to use in any fu-
ture cost-effectiveness analysis of DAPT will of course
be dependent on the country for which the analysis is
being conducted. The utility decrements estimated in
our elicitation exercise have been derived from a rele-
vant patient population, based on standardised defini-
tions of minor and major bleeding events, using a
validated HRQoL instrument for the patient population
of interest and have been valued using general popula-
tion tariffs. We therefore recommend that our utility
decrements (choosing the ones most appropriate for the
country to which the analysis will be applied) be used in
future cost-effectiveness analyses of DAPT, particularly
for minor bleeding events where existing evidence is
rather limited. In addition, rather than using a range of
alternative sources in cost-effectiveness models, some
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which may be unreliable, we recommend that future re-
search focuses on quantifying the value of reducing deci-
sion uncertainty for our estimated utility decrements.
This research would demonstrate whether conducting a
larger, more robust study to collect additional informa-
tion concerning the HRQoL impact of minor and major
bleeds for patients taking DAPT post-coronary interven-
tion would be an efficient use of resources.
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